Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: working on updating assumption 2 per Sandy's comments

...

Page properties
Title

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0)

CDISC ReferenceQuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
QRS Short Name

PRO-CTCAE V1.0

QRS Permission StatusApproved
TeamCDISC Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0
StatusDRAFT
Date20222023-1112-0108
NotesThis supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials.
Known Issue
  • The concept of “conditional branching” in QRS instruments is when the instrument directs the subject to another item of the instrument based on the result of a response compare for a given condition. This concept was reviewed with the CDISC standards teams and it was agreed to use this term instead of “logically skipped item” moving forward for this QRS instrument use case. A new QRS variable named “QSCBRFL” with the description of “Conditional “Conditionally Branched Item Indicator” Flag” has been requested approved for release in SDTMIG v4.0. This new variable will streamline the data representation of conditional conditionally branched items.


Revision History

DateVersion
20222023-1112-01081.0 Draft
Info

The CDISC PRO-CTCAE V1.0 supplement Version 1.0 was developed based on the NCI/NIH PRO-CTCAE® website. The website’s PRO-CTCAE Version 1.0 release notes indicate the revisions made by NCI/NIH on the PRO-CTCAE 1.0 measurement system. The measurement system version is 1.0 based on the website's release notes (specific correction of typographical errors in the different CRF translations). NCI/NIH will notify CDISC of any major changes in the future that would require a change control to the CDISC PRO-CTCAE V1.0 supplement version.

© 2022 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved. 

1 Introduction

This document describes the CDISC implementation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Item Library Version 1.0 (PRO-CTCAE V1.0).

...

The CDISC Intellectual Property Policy can be found on the CDISC website at: https://www.cdisc.org/about/bylaws.

1.1 Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the SDTMIG for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material.

CDISC specifies how to structure the data that has been collected in a database, not what should be collected or how to conduct clinical assessments or protocols. CDISC disclaims any liability for your use of this material.

Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument. 

2 Copyright Status

The PRO-CTCAE® Measurement System is owned exclusively by National Cancer Institute (NCI). Use of the PRO-CTCAE V1.0 is subject to NCI terms of use policy listed on the website. Based on these terms of use, CDISC considers this instrument exempt from copyright restrictions. CDISC has included this supplement in the CDISC inventory of QRS data standards supplements. Hence, CDISC developed QSTESTCD and QSTEST for each item based on the actual text on the measurement system

The CDISC documentation of this measurement system consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values (referred to hereafter as annotated Item Library v1.0 form).

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to copyright holder or any additional cost to users of the measurement system beyond the normal licenses fees charged by the copyright holder.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

References for the PRO-CTCAE V1.0:

...

  • These materials discuss and/or include the PRO-CTCAE® Item Library Version 1.0 (PRO-CTCAE V1.0). The PRO-CTCAE® Measurement System is owned exclusively by the National Cancer Institute. No part of the PRO-CTCAE® Measurement System may be adapted, altered, amended, abridged, modified, condensed, made into derivative works, or translated without prior written permission from the US National Cancer Institute. PRO-CTCAE is a registered trademark of the US Department of Health & Human Services. All rights reserved. For additional terms of use and to access PRO-CTCAE® Measurement System content, visit https://healthcaredelivery.cancer.gov/pro-ctcae/.
  • The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the National Cancer Institute at the National Institutes of Health, Bethesda, Maryland, USA. Use of the PRO-CTCAE is subject to NCI’s Terms of Use. PRO-CTCAE Measurement System content should be downloaded using the Instruments & Form Builder link (https://healthcaredelivery.cancer.gov/pro-ctcae/).

The CDISC documentation of this measurement system consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values (referred to hereafter as annotated Item Library v1.0 form).

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to the owner, trademark holder, or users of the measurement system.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

References for the PRO-CTCAE V1.0:

...

  • Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).J Natl Cancer Inst 2014 Sep 29;106(9)).
  • National Institutes of Health – National Cancer Institute, Division of Cancer Control & Population Sciences. (2017, July 2) https://healthcaredelivery.cancer.gov/pro-ctcae/overview.html

3 The QS Domain Model

3.1 Assumptions for the QS Domain Model

All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the PRO-CTCAE V1.0 are listed below.

...

  1. As a CDISC QRS standard, the supplement name is PRO-CTCAE V1.0, as provided in this document. As an item library, sponsors may select items from the overall library as a subset of items with the same CDISC Controlled Terminology as appropriate for the condition being studied. It is the user's responsibility to identify the subset of items used from the overall PRO-CTCAE V1.0 Quick Guide to the Item Library. The subsetted PRO-CTCAE V1.0 user's measurement system should be titled "PRO-CTCAE sponsor-specified symptoms..." based on the sponsor's discretion when they identify the specific items being used. This will distinctly describe the subsetted measurement system from the overall PRO-CTCAE V1.0. The form builder does not represent the Quick Guide to the Item Library symptom term when creating forms with selected symptoms. Users need to reference the annotated Item Library v1.0 form to obtain the related symptom term for forms based on selected symptoms. 
  2. For the PRO-CTCAE V1.0, QSORRES is represented with the text description; the numeric rating is represented in the standardized character and numeric result variables QSSTRESC and QSSTRESN. Please see the PRO-CTCAE website FAQs for more details on the numeric responsesThe responses for the PRO-CTCAE V1.0 are as follows:
    1. Depending on the symptomatic adverse event (AE) being measured, items assessing symptom presence/absence are rated as follows:Items are rated on a binary response scale and rated from 1-0 (e.g., 1 = “Yes” and 0 = “No”)Items rated on a multiple (more than 2) response scale and rated from 1-0 (e.g., 1 = “Yes”, 0 = “No”, and “Not applicable”(i.e., 0 = “No” and 1 = “Yes”)
    2. Items assessing symptom frequency are rated on a 5-point scale and are rated  are rated from 0-4 (i.e.g., 0 = “Never”, 1 = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, and 4 = “Almost constantly”).
    3. Items assessing symptom severity are rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”).QSTESTCD=PT01036A assessing symptom severity is rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”, and "Not applicable")
    4. Items assessing symptom interference are rated on a 5-point scale and are rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
    5. Items assessing symptom amount are rated on a 5-point scale and rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
    6. QSTESTCD = "PT01066A " to "PT01071A" sexual symptoms have specific responses.
      1. QSTESTCD=PT01069A and QSTESTCD=PT01070A assessing sexual symptom presence/absence are rated on multiple (more than 2) response scale and rated from 1-0 (e.g., 1 = “Yes” and 0 = “No”, “Not sexually active”, and “Prefer not to answer”).
      2. QSTESTCD=PT01066A, PT01068A, and PT01071A assessing sexual symptom severity are rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”, , and 4 = “Very severe”, "Not sexually active", and “Prefer not to answer”).

      3. QSTESTCD = "PT01067A" assessing sexual symptom frequency is rated on a 5-point scale rated from 0-4 (e.g., 0 = “Never”, 1 = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, 4 = “Almost constantly”, "Not sexually active", and “Prefer not to answer”).
    7. Selected items include additional response options such as "Not applicable", "Not sexually active", and "Prefer not to answer". Users will need to apply a customized value to each of these (e.g., -99 = "Not applicable", 999 = "Not sexually active", and “Prefer 9999 = "Prefer not to answer”answer"). For example,
      1. QSTESTCD= "PT01067A" assessing sexual symptom frequency is rated on a 5-point scale rated PT01036A assessing symptom severity is rated from 0-4 (e.g., 0 = “Never”“None”, 1 = “Rarely”“Mild”, 2 = “Occasionally”“Moderate”, 3 = “Frequently”“Severe”, and 4 = “Almost constantly”, “Very severe”. The response "Not sexually active", and “Prefer not to answer”).applicable" is also given and could be provided a value of -99.)
  3. The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" through "PT01091A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" through "PT01091B").
  4. PRO-CTCAE V1.0 total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., no total score nor symptom-specific scores are calculated).
  5. The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D"). Please see the PRO-CTCAE website for more details on the evaluation interval.
  6. Items are divided into 15 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping Strategy, for a list of these subcategory values. 
    1. The symptomatic AE being measured by a given item (e.g., the Symptom Term represented on the CRF corresponding to a given item) is stored in the SUPPQS dataset with the QNAM = "QSSYMPTM". This matches the symptom term identified in the PRO-CTCAE V1.0 Quick guide to the Item Library. The exception to this is the solicited verbatim symptom terms QSTESTCD = "PT01081 to PT01091B"with QNAM = "OTHER SYMPTOMS".
  7. Conditional branching is recommended by NCI/NIH in the conduct of the electronic version of the PRO-CTCAE V1.0 for symptom terms that have 2 or more items. The logic branches from frequency, then to severity, then to interference. For example, if frequency is > (greater than) never, next pose the severity question, and if severity > none, pose the interference question. Please see the PRO-CTCAE website for more details on the electronic conditional branching approach.
    1. When a paper version is administered, conditional branching does not apply.
  8. Some items on the PRO-CTCAE may be not done due to conditional branching per the electronic instrument instructions as described in assumption 7. A record is created with the assigned responses based on the PRO-CTCAE V1.0 website FAQ and a QS supplemental qualifier variable is used to indicate an item was conditionally branched. Per NIH, these items are assigned values as follows: severity items are assigned responses of "None" and 0; interference items are assigned "Not at all" and 0. When an item is not done due to conditional branching, it is represented as follows:
    1. QNAM = “QSCBRFL”, QLABEL =

  9. “Conditional
    1. “Conditionally Branched Item

  10. Indicator
    1. Flag “, QVAL = “Y” (this is a QS supplemental qualifier variable) 

    2. QSORRES

      1. For severity items, QSORRES = "None"

      2. For interference items, QSORRES = "Not at all"
    3. QSSTRESC = 0 and QSSTRESN = 0
  11. Records are created in qs.xpt for every item on the sponsor's version of the instrument. In the conduct of the PRO-CTCAE V1.0 NIH expects responses for each item and there should be no missing responses. 
    1. For items not done due to conditional branching, refer to assumption 8.
    2. In the unexpected situation where the reason is unknown, then QSORRES, QSSTRESC, and QSSTRESN are all missing; QSSTAT = "NOT DONE"; and QSREASND is missing.
  12. The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSLANGDC". See the PRO-CTCAE V1.0 website for a list of available language translations.
  13. Terminology
    1. QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PRO-CTCAE V1.0 QS Domain Model

The PRO-CTCAE V1.0 example below shows the terminology used to implement the measurement system in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.This result is then represented as a standard numeric score in QSSTRESN and as a standard character representation in QSSTRESC.

...

The SUPPQS dataset shows the items in the QS dataset which have assigned responses (QSDRVFL QSCBRFL = "Y") due to electronic conditional branching and also relates the symptom terms from the annotated Item Library v1.0 form to each symptom item represented in the QS dataset.

Dataset wrap
Namesuppqs
Dataset2
tableidsuppqs
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVALQORIG
STUDYXQS23-P0001QSSEQ21QSCBRFLConditional Branching Conditionally Branched Item IndicatorFlagYASSIGNED
STUDYXQS23-P0001QSSEQ25QSCBRFLConditional Branching Conditionally Branched Item IndicatorFlagYASSIGNED
STUDYXQS23-P0001QSSEQ26QSCBRFLConditional Branching Conditionally Branched Item IndicatorFlagYASSIGNED
STUDYXQS23-P0001QSTESTCDPT01001AQSSYMPTMSymptom TermDRY MOUTHCRF
STUDYXQS23-P0001QSTESTCDPT01002AQSSYMPTMSymptom TermDIFFICULTY SWALLOWINGCRF
STUDYXQS23-P0001QSTESTCDPT01003AQSSYMPTMSymptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01003BQSSYMPTMSymptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01004AQSSYMPTMSymptom TermCRACKING AT THE CORNERS OF THE MOUTH (CHEILOSIS/CHEILITIS)CRF
STUDYXQS23-P0001QSTESTCDPT01005AQSSYMPTMSymptom TermVOICE QUALITY CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01006AQSSYMPTMSymptom TermHOARSENESSCRF
STUDYXQS23-P0001QSTESTCDPT01007AQSSYMPTMSymptom TermTASTE CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01008AQSSYMPTMSymptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01008BQSSYMPTMSymptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01009AQSSYMPTMSymptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01009BQSSYMPTMSymptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01010AQSSYMPTMSymptom TermVOMITINGCRF
STUDYXQS23-P0001QSTESTCDPT01010BQSSYMPTMSymptom TermVOMITINGCRF
STUDYXQS23-P0001QSTESTCDPT01011AQSSYMPTMSymptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01011BQSSYMPTMSymptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01012AQSSYMPTMSymptom TermGASCRF
STUDYXQS23-P0001QSTESTCDPT01013AQSSYMPTMSymptom TermBLOATINGCRF
STUDYXQS23-P0001QSTESTCDPT01013BQSSYMPTMSymptom TermBLOATINGCRF
STUDYXQS23-P0001QSTESTCDPT01014AQSSYMPTMSymptom TermHICCUPSCRF
STUDYXQS23-P0001QSTESTCDPT01014BQSSYMPTMSymptom TermHICCUPSCRF
STUDYXQS23-P0001QSTESTCDPT01015AQSSYMPTMSymptom TermCONSTIPATIONCRF
STUDYXQS23-P0001QSTESTCDPT01016AQSSYMPTMSymptom TermDIARRHEACRF
STUDYXQS23-P0001QSTESTCDPT01017AQSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017BQSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017CQSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01018AQSSYMPTMSymptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01018BQSSYMPTMSymptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01019AQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01019BQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01020AQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01020BQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01021AQSSYMPTMSymptom TermWHEEZINGCRF
STUDYXQS23-P0001QSTESTCDPT01022AQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022BQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022CQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01023AQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01023BQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01024AQSSYMPTMSymptom TermRASHCRF
STUDYXQS23-P0001QSTESTCDPT01025AQSSYMPTMSymptom TermSKIN DRYNESSCRF
STUDYXQS23-P0001QSTESTCDPT01026AQSSYMPTMSymptom TermACNECRF
STUDYXQS23-P0001QSTESTCDPT01027AQSSYMPTMSymptom TermHAIR LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01028AQSSYMPTMSymptom TermITCHINGCRF
STUDYXQS23-P0001QSTESTCDPT01029AQSSYMPTMSymptom TermHIVESCRF
STUDYXQS23-P0001QSTESTCDPT01030AQSSYMPTMSymptom TermHAND-FOOT SYNDROMECRF
STUDYXQS23-P0001QSTESTCDPT01031AQSSYMPTMSymptom TermNAIL LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01032AQSSYMPTMSymptom TermNAIL RIDGINGCRF
STUDYXQS23-P0001QSTESTCDPT01033AQSSYMPTMSymptom TermNAIL DISCOLORATIONCRF
STUDYXQS23-P0001QSTESTCDPT01034AQSSYMPTMSymptom TermSENSITIVITY TO SUNLIGHTCRF
STUDYXQS23-P0001QSTESTCDPT01035AQSSYMPTMSymptom TermBED/PRESSURE SORESCRF
STUDYXQS23-P0001QSTESTCDPT01036AQSSYMPTMSymptom TermRADIATION SKIN REACTIONCRF
STUDYXQS23-P0001QSTESTCDPT01037AQSSYMPTMSymptom TermSKIN DARKENINGCRF
STUDYXQS23-P0001QSTESTCDPT01038AQSSYMPTMSymptom TermSTRETCH MARKSCRF
STUDYXQS23-P0001QSTESTCDPT01039AQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01039BQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01040AQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01040BQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01041AQSSYMPTMSymptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01041BQSSYMPTMSymptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01042AQSSYMPTMSymptom TermFLASHING LIGHTSCRF
STUDYXQS23-P0001QSTESTCDPT01043AQSSYMPTMSymptom TermVISUAL FLOATERSCRF
STUDYXQS23-P0001QSTESTCDPT01044AQSSYMPTMSymptom TermWATERY EYESCRF
STUDYXQS23-P0001QSTESTCDPT01044BQSSYMPTMSymptom TermWATERY EYESCRF
STUDYXQS23-P0001QSTESTCDPT01045AQSSYMPTMSymptom TermRINGING IN EARSCRF
STUDYXQS23-P0001QSTESTCDPT01046AQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01046BQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01047AQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01047BQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01048AQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048BQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048CQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01049AQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049BQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049CQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01050AQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01050BQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01050CQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051AQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051BQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051CQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01052AQSSYMPTMSymptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCDPT01052BQSSYMPTMSymptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCDPT01053AQSSYMPTMSymptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCDPT01053BQSSYMPTMSymptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCDPT01054AQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01054BQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01054CQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01055AQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01055BQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01055CQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01056AQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCDPT01056BQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCDPT01056CQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCDPT01057AQSSYMPTMSymptom TermIRREGULAR PERIODS/VAGINAL BLEEDINGCRF
STUDYXQS23-P0001QSTESTCDPT01058AQSSYMPTMSymptom TermMISSED EXPECTED MENSTRUAL PERIODCRF
STUDYXQS23-P0001QSTESTCDPT01059AQSSYMPTMSymptom TermVAGINAL DISCHARGECRF
STUDYXQS23-P0001QSTESTCDPT01060AQSSYMPTMSymptom TermVAGINAL DRYNESSCRF
STUDYXQS23-P0001QSTESTCDPT01061AQSSYMPTMSymptom TermPAINFUL URINATIONCRF
STUDYXQS23-P0001QSTESTCDPT01062AQSSYMPTMSymptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCDPT01062BQSSYMPTMSymptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCDPT01063AQSSYMPTMSymptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCDPT01063BQSSYMPTMSymptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCDPT01064AQSSYMPTMSymptom TermCHANGE IN USUAL URINE COLORCRF
STUDYXQS23-P0001QSTESTCDPT01065AQSSYMPTMSymptom TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01065BQSSYMPTMSymptom TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01066AQSSYMPTMSymptom TermACHIEVE AND MAINTAIN ERECTIONCRF
STUDYXQS23-P0001QSTESTCDPT01067AQSSYMPTMSymptom TermEJACULATIONCRF
STUDYXQS23-P0001QSTESTCDPT01068AQSSYMPTMSymptom TermDECREASED LIBIDOCRF
STUDYXQS23-P0001QSTESTCDPT01069AQSSYMPTMSymptom TermDELAYED ORGASMCRF
STUDYXQS23-P0001QSTESTCDPT01070AQSSYMPTMSymptom TermUNABLE TO HAVE ORGASMCRF
STUDYXQS23-P0001QSTESTCDPT01071AQSSYMPTMSymptom TermPAIN W/SEXUAL INTERCOURSECRF
STUDYXQS23-P0001QSTESTCDPT01072AQSSYMPTMSymptom TermBREAST SWELLING AND TENDERNESSCRF
STUDYXQS23-P0001QSTESTCDPT01073AQSSYMPTMSymptom TermBRUISINGCRF
STUDYXQS23-P0001QSTESTCDPT01074AQSSYMPTMSymptom TermCHILLSCRF
STUDYXQS23-P0001QSTESTCDPT01074BQSSYMPTMSymptom TermCHILLSCRF
STUDYXQS23-P0001QSTESTCDPT01075AQSSYMPTMSymptom TermINCREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCDPT01075BQSSYMPTMSymptom TermINCREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCDPT01076AQSSYMPTMSymptom TermDECREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCDPT01077AQSSYMPTMSymptom TermHOT FLASHESCRF
STUDYXQS23-P0001QSTESTCDPT01077BQSSYMPTMSymptom TermHOT FLASHESCRF
STUDYXQS23-P0001QSTESTCDPT01078AQSSYMPTMSymptom TermNOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCDPT01078BQSSYMPTMSymptom TermNOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCDPT01079AQSSYMPTMSymptom TermPAIN AND SWELLING AT INJECTION SITECRF
STUDYXQS23-P0001QSTESTCDPT01080AQSSYMPTMSymptom TermBODY ODORCRF
STUDYXQS23-P0001QSTESTCDPT01081QSSYMPTMSymptom TermANY OTHER SYMPTOMS REPORTEDCRF
STUDYXQS23-P0001QSTESTCDPT01082AQSSYMPTMSymptom TermOTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCDPT01082BQSSYMPTMSymptom TermOTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCDPT01083AQSSYMPTMSymptom TermOTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCDPT01083BQSSYMPTMSymptom TermOTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCDPT01084AQSSYMPTMSymptom TermOTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCDPT01084BQSSYMPTMSymptom TermOTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCDPT01085AQSSYMPTMSymptom TermOTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCDPT01085BQSSYMPTMSymptom TermOTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCDPT01086AQSSYMPTMSymptom TermOTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCDPT01086BQSSYMPTMSymptom TermOTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCDPT01087AQSSYMPTMSymptom TermOTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCDPT01087BQSSYMPTMSymptom TermOTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCDPT01088AQSSYMPTMSymptom TermOTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCDPT01088BQSSYMPTMSymptom TermOTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCDPT01089AQSSYMPTMSymptom TermOTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCDPT01089BQSSYMPTMSymptom TermOTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCDPT01090AQSSYMPTMSymptom TermOTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCDPT01090BQSSYMPTMSymptom TermOTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCDPT01091AQSSYMPTMSymptom TermOTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCDPT01091BQSSYMPTMSymptom TermOTHER SYMPTOM 10CRF

...

Dataset wrap
Namesuppqsxx
Dataset2
tableidsuppqsxx
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVALQORIG
STUDYXQS23-P0001QSTESTCDPT01019AQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01019BQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01020AQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01020BQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01021AQSSYMPTMSymptom TermWHEEZINGCRF
STUDYXQS23-P0001QSTESTCDPT01022AQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022BQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022CQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01023AQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01023BQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01039AQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01039BQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01040AQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01040BQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01046AQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01046BQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01047AQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01047BQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01081QSSYMPTMSymptom TermANY OTHER SYMPTOMS REPORTEDCRF
STUDYXQS23-P0001QSTESTCDPT01082AQSSYMPTMSymptom TermOTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCDPT01082BQSSYMPTMSymptom TermOTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCDPT01083AQSSYMPTMSymptom TermOTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCDPT01083BQSSYMPTMSymptom TermOTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCDPT01084AQSSYMPTMSymptom TermOTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCDPT01084BQSSYMPTMSymptom TermOTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCDPT01085AQSSYMPTMSymptom TermOTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCDPT01085BQSSYMPTMSymptom TermOTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCDPT01086AQSSYMPTMSymptom TermOTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCDPT01086BQSSYMPTMSymptom TermOTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCDPT01087AQSSYMPTMSymptom TermOTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCDPT01087BQSSYMPTMSymptom TermOTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCDPT01088AQSSYMPTMSymptom TermOTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCDPT01088BQSSYMPTMSymptom TermOTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCDPT01089AQSSYMPTMSymptom TermOTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCDPT01089BQSSYMPTMSymptom TermOTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCDPT01090AQSSYMPTMSymptom TermOTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCDPT01090BQSSYMPTMSymptom TermOTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCDPT01091AQSSYMPTMSymptom TermOTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCDPT01091BQSSYMPTMSymptom TermOTHER SYMPTOM 10CRF


4 SDTM Mapping Strategy

This section is used for reference regarding the CRF data capture and to understand the alignment of the measurement system to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSSTRESC, and QSSTRESN) should be populated.

QSSCAT alignment with QSTESTCD

As stated in Section 3.1 assumptions, Assumptions, the PRO-CTCAE V1.0 symptom terms are grouped into subcategories as represented in the Quick Guide to the Item Library. The table below includes the subcategory names along with the applicable question numbers for each category. The values of the subcategories are used to populate QSSCAT and are annotated

Jira
showSummaryfalse
serverIssue Tracker (JIRA)
serverId85506ce4-3cb3-3d91-85ee-f633aaaf4a45
keyQRSSUPP-490
on the CRF.

QSSCATQSTESTCD
ORALPT01001A - PT01006A
GASTROINTESTINALPT01007A - PT01018B
RESPIRATORYPT01019A - PT01021A
CARDIO/CIRCULATORYPT01022A - PT01023B
CUTANEOUSPT01024A - PT01038A
NEUROLOGICALPT01039A - PT01040B
VISUAL/PERCEPTUALPT01041A - PT01045A
ATTENTION/MEMORYPT01046A - PT01047B
PAINPT01048A - PT01051C
SLEEP/WAKEPT01052A - PT01053B
MOODPT01054A - PT01056C
GYNECOLOGIC/URINARYPT01057A - PT01065B
SEXUALPT01066A - PT01071A
MISCELLANEOUSPT01072A - PT01080A
OTHER SYMPTOMPT01081 - PT01091B

...

QSORRES

QSSTRESC

QSSTRESN

Yes11
No00
Not applicableNot applicable

5 Supplemental Qualifier Name Codes

The following table contains additional standard name codes for use in the Supplement Qualifiers for Questionnaires (SUPPQS) special purpose dataset.

PRO-CTCAE V1.0 conditional branching items

QNAMQLABELQVAL
QSCBRFLConditional Conditionally Branched Item IndicatorFlag

Y

PRO-CTCAE V1.0 supported languages

...